Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Lung Cancer

Free Subscription 16.02.2026 1 AJR Am J Roentgenol 1 Ann Oncol 7 Ann Surg Oncol 1 Ann Thorac Surg 1 Arch Bronconeumol 7 BMC Cancer 1 Br J Cancer 1 Cancer Cell 1 Cancer Lett 2 Chest 1 Clin Cancer Res 3 Clin Lung Cancer 1 Eur J Cancer 5 Eur J Cardiothorac Surg 1 Int J Cancer 1 J Clin Oncol 1 J Thorac Oncol 1 JAMA Oncol 1 Lancet Oncol 23 Lung Cancer 1 Mol Cancer Ther 1 Nat Genet 1 Oncogene 1 Oncol Rep 1 Oncologist 6 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. AHN Y, Lee SM, Kim Y, Kim C, et al
   Central Tumor Location in Resected Lung Adenocarcinoma: Association With Recurrence and Survival Outcomes.
   AJR Am J Roentgenol. 2026;226:e2533503.
   PubMed         Abstract available
   
   

   
   Ann Oncol

2. WANG Y, Rosell R, Hirsch FR, Lu S, et al
   Emerging options and future strategies in immunotherapy for advanced lung squamous-cell carcinoma.
   Ann Oncol. 2026;37:289-313.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

3. FAJARDO V, Garcia-Cabo B, Rami-Porta R, Martinez-Palau M, et al
   ASO Visual Abstract: Systematic endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) compared with targeted EBUS-TBNA for mediastinal staging of locally advanced non-small-cell lung cancer.
   Ann Surg Oncol. 2026 Feb 11. doi: 10.1245/s10434-025-18908.
   PubMed        
   
   
4. CHEN Q, Yao M, Chen Z, Liu S, et al
   ASO Visual Abstract: N-LODDS: A Novel Integrated Lymph Node Staging System Enhancing Prognostic Accuracy in Non-Small-Cell Lung Cancer.
   Ann Surg Oncol. 2026 Feb 10. doi: 10.1245/s10434-026-19202.
   PubMed        
   
   
5. WEI X, Zhang Y, Tian B, Xie S, et al
   ASO Author Reflections: Balancing Robotic Technology, Incision Strategy, and Patient Experience in Lung Cancer Surgery.
   Ann Surg Oncol. 2026 Feb 10. doi: 10.1245/s10434-025-18954.
   PubMed        
   
   
6. WEI X, Yu H, Dai W, Huang L, et al
   Long-Term Patient-Reported Outcomes after Multiport Robot-Assisted Surgery versus Video-Assisted Surgery for Lung Cancer: An Observational Cohort Study.
   Ann Surg Oncol. 2026 Feb 10. doi: 10.1245/s10434-025-18834.
   PubMed         Abstract available
   
   
7. WEI X, Yu H, Dai W, Huang L, et al
   ASO Visual Abstract: Long-Term Patient-Reported Outcomes After Multiport Robot-Assisted Surgery Versus Video-Assisted Surgery for Lung Cancer: An Observational Cohort Study.
   Ann Surg Oncol. 2026 Feb 9. doi: 10.1245/s10434-025-19049.
   PubMed        
   
   
8. KHAN W, Ali T, Bilal M, Ahmad W, et al
   Evaluating Surgical Approaches in Early NSCLC: A Meta-Analysis of Robot-Assisted and Video-Assisted Techniques.
   Ann Surg Oncol. 2026;33:2123-2136.
   PubMed         Abstract available
   
   
9. ZHENG C, Cai Y, Miao J, Sun C, et al
   Explainable PET-Based Habitat Modeling for Predicting Postoperative Recurrence Risk in Invasive Lung Adenocarcinoma.
   Ann Surg Oncol. 2026;33:2035-2046.
   PubMed         Abstract available
   
   

   
   Ann Thorac Surg

10. MCCRACKEN AL, Antonoff MB
    When Access Is Standardized, Outcomes Converge in Early-Stage Lung Cancer.
    Ann Thorac Surg. 2026 Feb 13:S0003-4975(26)00131.
    PubMed        
    
    

    
    Arch Bronconeumol

11. PAPAVASSILIOU KA, Papavassiliou AG
    Proposal for a Hybrid Anatomical and Biological Staging System in Lung Cancer.
    Arch Bronconeumol. 2026 Feb 4:S0300-2896(26)00049.
    PubMed        
    
    

    
    BMC Cancer

12. ADAMSON B, van Boemmel-Wegmann S, Horne E, Soares S, et al
    Real-world evidence from Germany: representativeness analysis and mortality endpoint validation in electronic health record-derived oncology cohorts.
    BMC Cancer. 2026;26:202.
    PubMed         Abstract available
    
    
13. KOURIE HR, Farhat C, Zouein J, Chebly A, et al
    Updated incidence of EGFR mutation in Middle Eastern patients with non-small cell lung cancer: a 7-year study in a Lebanese institution.
    BMC Cancer. 2026 Feb 9. doi: 10.1186/s12885-025-14839.
    PubMed        
    
    
14. WANG W, Hu X, Luan Y, Chen W, et al
    A multi-branch ensemble learning framework for detection of non-small cell lung cancer via T-cell receptor sequencing.
    BMC Cancer. 2026 Feb 11. doi: 10.1186/s12885-026-15714.
    PubMed        
    
    
15. TAO D, Lei H, Sun L, Wang L, et al
    Nomogram-based prediction of checkpoint inhibitor pneumonitis in lung cancer patients.
    BMC Cancer. 2026 Feb 12. doi: 10.1186/s12885-026-15729.
    PubMed         Abstract available
    
    
16. MATSUURA S, Kita K, Matsushita K, Nagasaki T, et al
    Pretreatment clinical and hematological predictors of efficacy and immune-related adverse events in patients with advanced non-small cell lung cancer receiving first-line chemotherapy combined with immune checkpoint inhibitors.
    BMC Cancer. 2026 Feb 12. doi: 10.1186/s12885-026-15733.
    PubMed        
    
    
17. DANG Y, Li X, Cheng Y, Pan S, et al
    Association between four indirect indicators of insulin resistance and lung cancer: evidence from UK biobank and Mendelian randomization analysis.
    BMC Cancer. 2026 Feb 13. doi: 10.1186/s12885-026-15697.
    PubMed        
    
    
18. ZHONG W, Wu S, Zhu R, Shi H, et al
    Optimal sequencing of brain radiotherapy and immunotherapy for patients with non-small cell lung cancer and driver gene-negative, asymptomatic brain metastases.
    BMC Cancer. 2026 Feb 15. doi: 10.1186/s12885-026-15706.
    PubMed        
    
    

    
    Br J Cancer

19. RAMESH V, Demirdizen M, Pinna L, Doktor TK, et al
    Pan-cancer analysis of pyrimidine metabolism reveals signaling pathways connections with chemoresistance role.
    Br J Cancer. 2026;134:799-810.
    PubMed         Abstract available
    
    

    
    Cancer Cell

20. PENG F, Sinjab A, Dai Y, Treekitkarnmongkol W, et al
    Multimodal spatial-omics reveal co-evolution of alveolar progenitors and proinflammatory niches in progression of lung precursor lesions.
    Cancer Cell. 2026;44:321-339.
    PubMed         Abstract available
    
    

    
    Cancer Lett

21. XU Z, Gao J, Ye C, Li Y, et al
    PPP4C restores YAP1 activity by modulating MST4 phosphorylation to enhance immunosuppression and augment tumor growth in non-small cell lung cancer.
    Cancer Lett. 2026 Feb 12:218306. doi: 10.1016/j.canlet.2026.218306.
    PubMed         Abstract available
    
    

    
    Chest

22. CHAUDHURI N, Chaudhuri V
    Surgical Management of Early Lung Cancer: Is Robotic-Assisted Thoracic Surgery or Video-Assisted Thoracoscopic Surgery Better?
    Chest. 2026;169:e86-e87.
    PubMed        
    
    
23. STUDTS JL, Knight JR, Yates AR, Alexander JL, et al
    Quality Implementation of Lung Cancer Screening System (QUILS 1.0): A system to support high-quality delivery of lung cancer screening in diverse settings.
    Chest. 2026 Feb 11:S0012-3692(26)00145-5. doi: 10.1016/j.chest.2025.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

24. CHEN M, Bulat I, Maglakelidze M, Li N, et al
    Subcutaneously Administered Tislelizumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Pharmacokinetics and Safety Results from the BGB-A317-103 Phase I Study.
    Clin Cancer Res. 2026 Feb 11. doi: 10.1158/1078-0432.CCR-25-2173.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

25. SPIRA AI, Berz D, Jotte RM, Pachipala KK, et al
    Dose Escalation Trial of the Combination of Osimertinib and Quaratusugene Ozeplasmid Gene Therapy in Patients with Advanced NSCLC.
    Clin Lung Cancer. 2026;27:75-81.
    PubMed         Abstract available
    
    
26. REDDY K, Wang F, Cao Y, Gan GN, et al
    A Randomized Phase II Trial of Hypo-fractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction Versus Standard- Fractionated IMRT, Concurrent With Carboplatin/Paclitaxel and Followed by Consolidation Durvalumab, for Subjects W
    Clin Lung Cancer. 2026;27:98-105.
    PubMed         Abstract available
    
    
27. GOMES F, Gilding N, Tan V, Christoforou K, et al
    Impact of First-Line Maintenance Immunotherapy With or Without Pemetrexed for Non-Squamous Advanced/Metastatic Non-Small Cell Lung Cancer Lacking Targetable Mutations: A Real-World Analysis in England.
    Clin Lung Cancer. 2026 Jan 7:S1525-7304(25)00335.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

28. BOILEVE A, Mercier L, Bonnet B, Tarabay A, et al
    Lung-only metastatic pancreatic cancer: Differences in patients 'characteristics, molecular profile and survival.
    Eur J Cancer. 2026;235:116227.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

29. YANG Y, He H, Yu C, Sardari Nia P, et al
    Artificial Intelligence Models to Predict Recurrence Risk Prediction in Early-Stage Non-Small Cell Lung Cancer: A Systematic Review.
    Eur J Cardiothorac Surg. 2026;68:ezag072.
    PubMed         Abstract available
    
    
30. YANAGIHARA T, Miura K, Bernards N, Kitazawa S, et al
    Utility of Computed Tomography-Based Intraoperative Surgical Margin Evaluation in Wedge-Resected Lung Specimens.
    Eur J Cardiothorac Surg. 2026;68:ezag074.
    PubMed         Abstract available
    
    
31. RYO T, Yutaka Y, Hidaka Y, Sakanoue I, et al
    Evaluation of Radiofrequency Identification for Accurate Wedge Resection of Small Lung Lesions With Reference to Dye Marking.
    Eur J Cardiothorac Surg. 2026;68:ezag066.
    PubMed         Abstract available
    
    
32. BUZAS A, Pecsy B, Egyed K, Lada F, et al
    Spread Through Air Spaces is Significantly Associated With Brain Metastases in Less Than 2 cm Lung Adenocarcinomas.
    Eur J Cardiothorac Surg. 2026;68:ezag079.
    PubMed         Abstract available
    
    
33. MEI J, Liu Z, Wu Q, Sun T, et al
    A Prospective, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Augmented Reality Navigation-Guided Pulmonary Nodule Localization System.
    Eur J Cardiothorac Surg. 2026;68:ezag049.
    PubMed         Abstract available
    
    

    
    Int J Cancer

34. LI W, Ge Y, Zhang Z, Gan J, et al
    Construction and immunotherapy application of lung cancer organoids.
    Int J Cancer. 2026 Feb 12. doi: 10.1002/ijc.70347.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

35. ZHAO J, Graetz I, Howard D, Han X, et al
    Medicaid Expansion and Stage at Diagnosis, Timely Initiation and Receipt of Guideline-Concordant Treatment, and Survival Among People With Non-Small Cell Lung Cancer.
    J Clin Oncol. 2026 Feb 13:JCO2501892. doi: 10.1200/JCO-25-01892.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

36. ZALCMAN G, Madroszyk A, Guenzi E, Dayen C, et al
    Four-Year outcomes of first-line Nivolumab plus ipilimumab for 6 months versus continuation in patients with advanced non-small-cell lung cancer Results of the randomized IFCT-1701 "DICIPLE" Phase III trial.
    J Thorac Oncol. 2026 Feb 12:103609. doi: 10.1016/j.jtho.2026.103609.
    PubMed         Abstract available
    
    

    
    JAMA Oncol

37. RAKAEE M, Nassar AH, Tafavvoghi M, Jabar F, et al
    Ancestry-Associated Performance Variability of Open-Source AI Models for EGFR Prediction in Lung Cancer.
    JAMA Oncol. 2026 Feb 12:e256430. doi: 10.1001/jamaoncol.2025.6430.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

38. CASASSUS B
    France plans national targeted lung cancer screening.
    Lancet Oncol. 2026 Feb 12:S1470-2045(26)00070.
    PubMed        
    
    

    
    Lung Cancer

39. ROLIM I, Lopez-Beltran A, Pantarotto M, de Sousa E, et al
    Altered bacteriome and mycobiome in small cell lung cancer: insights from microbial profiling.
    Lung Cancer. 2026;214:109315.
    PubMed         Abstract available
    
    
40. ALDER L, Mullikin TC, Lascola C, Sperduto PW, et al
    Broadening clinical trial inclusivity of patients with lung cancer and brain metastases utilizing the Graded Prognostic Assessment (GPA): A call to action.
    Lung Cancer. 2026;214:109317.
    PubMed         Abstract available
    
    
41. IACOVINO ML, Arenare L, Morabito A, Tiseo M, et al
    Validity and responsiveness of patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) among Italian lung cancer patients.
    Lung Cancer. 2026;214:109312.
    PubMed         Abstract available
    
    
42. AKAGI K, Taniguchi H, Fukuda M, Yamazaki T, et al
    Phase I study of amrubicin plus cisplatin and concurrent accelerated hyperfractionated thoracic radiotherapy for limited-stage small cell lung cancer.
    Lung Cancer. 2026;214:109310.
    PubMed         Abstract available
    
    
43. ILIE M, Heeke S, Rignol G, Pirlog R, et al
    Genomic landscape of stage 0-IA lung adenocarcinoma identified by on-site reflex targeted NGS.
    Lung Cancer. 2026;213:108943.
    PubMed         Abstract available
    
    
44. VASILIKI N, Vincent S, Zoe A, Michela S, et al
    Prevention and management of amivantamab-induced dermatologic toxicities: a European expert consensus and practical algorithm.
    Lung Cancer. 2026;213:108950.
    PubMed         Abstract available
    
    
45. BRASCIA D, Mangiameli G, Congedo MT, Mastromarino MG, et al
    Immune-inflammatory predictors of early and brain recurrence in young patients with resected non-small cell lung cancer.
    Lung Cancer. 2026;213:108946.
    PubMed         Abstract available
    
    
46. PAZ-ARES L, Veillon R, Majem M, Zhou C, et al
    Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.
    Lung Cancer. 2026;213:108788.
    PubMed         Abstract available
    
    
47. ZHOU C, Tang KJ, Liu B, Kim SW, et al
    Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.
    Lung Cancer. 2026;213:109302.
    PubMed         Abstract available
    
    
48. HASHIMOTO K, Takahara M, Ishii R, Uno T, et al
    Real-world occurrence of severe gastrointestinal bleeding in patients receiving amivantamab plus lazertinib: A two-case series among 25 consecutive cases.
    Lung Cancer. 2026;213:108947.
    PubMed         Abstract available
    
    
49. CHENG Y, Huang JJ, Zhu HY, Shao D, et al
    Prognostic value of baseline (18)F-FDG PET/CT metabolic parameters combined with clinical and pathological features in surgically resected ALK-positive non-small cell lung cancer.
    Lung Cancer. 2026;213:108948.
    PubMed         Abstract available
    
    
50. SCHNEIDER JL, Muzikansky A, Krueger E, Gainor JF, et al
    Combination therapy with lorlatinib and mitogen-activated protein kinase pathway inhibition in previously treated ALK- or ROS1-rearranged lung cancer.
    Lung Cancer. 2026;213:108945.
    PubMed         Abstract available
    
    
51. ABDEL-RAHMAN O, Taylor P, O'Brien M, Raskin J, et al
    Nintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG).
    Lung Cancer. 2026;213:108906.
    PubMed         Abstract available
    
    
52. KIM DH, Kim M, Youk J, Kim TM, et al
    Durvalumab-containing treatment for recurrent or metastatic pulmonary sarcomatoid carcinoma: A pooled post hoc analysis of two KCSG phase II trials.
    Lung Cancer. 2026;213:108916.
    PubMed         Abstract available
    
    
53. FEI X, Wu H, Li M, Yu J, et al
    FAM83A promotes the progression of lung squamous cell carcinoma by inducing the epithelial-mesenchymal transition and inhibiting apoptosis via ERK pathway.
    Lung Cancer. 2026;213:108917.
    PubMed         Abstract available
    
    
54. GANG X, Sun Y, Hao J, Zhao S, et al
    KRAS-mutant advanced NSCLC: efficacy and clinical outcomes from network meta-analysis and real-world evidence.
    Lung Cancer. 2026;213:108930.
    PubMed         Abstract available
    
    
55. LI M, Wang H, Zhang W, Lin D, et al
    Combined intrathecal therapy via Ommaya reservoir and whole-brain radiotherapy improves survival in EGFR-mutant NSCLC patients with leptomeningeal metastases: a real-world cohort study.
    Lung Cancer. 2026;213:108918.
    PubMed         Abstract available
    
    
56. HUANG WC, Kao TN, Liao SC, Lin MW, et al
    Psychological features and quality of life in low-dose CT lung cancer screening: a comparative analysis with general population data.
    Lung Cancer. 2026;213:109307.
    PubMed         Abstract available
    
    
57. NORDLING L, Backman M, Mezheyeuski A, Lindblad J, et al
    Incremental prognostic value of immune cell densities beyond clinical parameters in non-small cell lung cancer.
    Lung Cancer. 2026;213:108935.
    PubMed         Abstract available
    
    
58. WANG Y, Sun Z, Sridhar A, Ramalingam SS, et al
    Participation in lung cancer biospecimen studies: an analysis of the ECOG-ACRIN phase 3 E1505 and E5508 clinical trials.
    Lung Cancer. 2026;214:109304.
    PubMed         Abstract available
    
    
59. AHN Y, Lee GD, Choi S, Kim HR, et al
    Prognostic significance of consolidation-to-tumor ratio in stage IA solid predominant non-mucinous adenocarcinoma: a paradigm for risk stratification.
    Lung Cancer. 2026;213:108934.
    PubMed         Abstract available
    
    
60. CAVAZZONI A, Pagano Mariano M, Palladini A, Digiacomo G, et al
    Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRAS(G12C) inhibitors in NSCLC.
    Lung Cancer. 2026;213:108939.
    PubMed         Abstract available
    
    
61. CHEN J, McNierney D, Zein JG, Vaszar LT, et al
    Diagnostic performance of monarch robotic bronchoscopy with and without mobile cone-beam CT support.
    Lung Cancer. 2026;213:108910.
    PubMed         Abstract available
    
    

    
    Mol Cancer Ther

62. GUO H, Yue C, Ma D, Zhou J, et al
    VHH-based CAR-T cells targeting DLL3 show high efficacy in small-cell lung cancer models.
    Mol Cancer Ther. 2026 Feb 12. doi: 10.1158/1535-7163.MCT-25-0965.
    PubMed         Abstract available
    
    

    
    Nat Genet

63. HE Y, Lu W, Jee YH, Shih MY, et al
    Multi-trait and multi-ancestry genetic analysis of comorbid lung diseases and traits improves genetic discovery and polygenic risk prediction.
    Nat Genet. 2026;58:289-298.
    PubMed         Abstract available
    
    

    
    Oncogene

64. LI X, Liu S, Wang R, Wang X, et al
    Upconversion mesoporous silica nanoparticles co-delivering celecoxib and rose bengal enable multimodal immunogenic and anti-angiogenic therapy for spinal metastasis of non-small cell lung cancer.
    Oncogene. 2026 Feb 11. doi: 10.1038/s41388-026-03679.
    PubMed         Abstract available
    
    

    
    Oncol Rep

65. GUO M, Li H, Zhao Z, Wang Y, et al
    Suppressive role of SCN4B in the epithelial?mesenchymal transition of lung adenocarcinoma.
    Oncol Rep. 2026;55:68.
    PubMed         Abstract available
    
    

    
    Oncologist

66. CAVALHEIRO VJ, Sobral Filho DSR, de Oliveira GM, da Fonseca MDRN, et al
    Metastatic colorectal adenocarcinoma with APC and EGFR L858R co-mutations: a case report.
    Oncologist. 2026;31:oyaf421.
    PubMed         Abstract available
    
    

    
    PLoS One

67. LIN J, Xie X, Zheng X, Shi H, et al
    Global burden and trends of tracheal, bronchus, and lung cancer attributed to occupational exposure to polycyclic aromatic hydrocarbons in regions with different sociodemographic index, 1990-2021.
    PLoS One. 2026;21:e0342250.
    PubMed         Abstract available
    
    
68. KUMAR R, Massey S, Albogami S, Aloliqi AA, et al
    Identifying regulatory driver motifs in non-small cell lung carcinoma via a systematic approach.
    PLoS One. 2026;21:e0340798.
    PubMed         Abstract available
    
    
69. SHI Z, Fang Z, Qin Q, Gao Y, et al
    Exploring the toxicological mechanisms of Benzo[a]anthracene (BaA) exposure in lung adenocarcinoma (LUAD) via network toxicology, machine learning, and multi-dimensional bioinformatics analysis.
    PLoS One. 2026;21:e0340116.
    PubMed         Abstract available
    
    
70. SHAMSABAD FN, Salehi MH, Shams J, Ghazanfari T, et al
    Comparative inhibitory effects of zeolite, sepiolite, and kaolinite on A549 lung cancer cells.
    PLoS One. 2026;21:e0340270.
    PubMed         Abstract available
    
    
71. MIYASAKA Y, Yoshida H, Okano N, Shimada H, et al
    AI-based prediction of recurrence after carbon ion radiotherapy for early stage non-small cell lung cancer.
    PLoS One. 2026;21:e0342481.
    PubMed         Abstract available
    
    
72. JEON J, Kang J, Park JH, Lee JH, et al
    Sphingolipid metabolism-related genes B4GALNT1 and CERS4 as prognostic biomarkers in lung adenocarcinoma.
    PLoS One. 2026;21:e0340437.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

73. YANG Y, Wang S, Shi X, Chen X, et al
    Intravenous infusion of engineered megakaryocytes to produce oncolytic platelets in vivo for enhanced cancer immunotherapy.
    Proc Natl Acad Sci U S A. 2026;123:e2419694123.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum